Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.13) by 107.69 percent. This is a 52.63 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $32.832 million which missed the analyst consensus estimate of $67.456 million by 51.33 percent. This is a 47.62 percent increase over sales of $22.241 million the same period last year.